1. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Issue 10 (October 2022) Authors: Herman, Gary A; O'Brien, Meagan P; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Bar, Katharine J; Barnabas, Ruanne V; Barouch, Dan H; Cohen, Myron S; Hurt, Christopher B; Burwen, Dale R; Marovich, Mary A; Musser, Bret J; Davis, John D; Turner, Kenneth C; Mahmood,... Journal: Lancet infectious diseases Issue: Volume 22:Issue 10(2022) Page Start: 1444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P239 - BCRP gene deletion alters the gut microbiome in mice. (2020) Authors: Mukherjee, Kamalika; Ganguly, Samit; Lu, Jingjun; Schuetz, Erin Journal: Drug metabolism and pharmacokinetics Issue: Volume 35(2020)Supplement 1 Page Start: S95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. (September 2022) Authors: Isa, Flonza; Forleo-Neto, Eduardo; Meyer, Jonathan; Zheng, Wenjun; Rasmussen, Scott; Armas, Danielle; Oshita, Masaru; Brinson, Cynthia; Folkerth, Steven; Faria, Lori; Heirman, Ingeborg; Sarkar, Neena; Musser, Bret J.; Bansal, Shikha; O'Brien, Meagan P.; Turner, Kenneth C.; Ganguly, Samit; Mahmood... Journal: International journal of infectious diseases Issue: Volume 122(2022) Page Start: 585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗